Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124183154 | 12418315 | 4 | F | 201602 | 20160829 | 20160531 | 20160902 | PER | US-PFIZER INC-2016248192 | PFIZER | 70.00 | YR | M | Y | 122.00000 | KG | 20160902 | OT | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124183154 | 12418315 | 1 | PS | SUTENT | SUNITINIB MALATE | 1 | 50 MG, 1X/DAY | 21938 | 50 | MG | CAPSULE, HARD | QD | |||||||
| 124183154 | 12418315 | 2 | SS | SUTENT | SUNITINIB MALATE | 1 | UNK, CYCLIC (ON FOR 4 WEEKS AND OFF FOR 2 WEEKS) | 21938 | CAPSULE, HARD | ||||||||||
| 124183154 | 12418315 | 3 | SS | SUTENT | SUNITINIB MALATE | 1 | 50 MG, 1X/DAY | 21938 | 50 | MG | CAPSULE, HARD | QD | |||||||
| 124183154 | 12418315 | 4 | SS | SUTENT | SUNITINIB MALATE | 1 | UNK, CYCLIC (TAKING 30 DAYS ON AND 14 DAYS OFF/ CHANGING IT TO 2 WEEKS ON AND 1 WEEK OFF) | 21938 | CAPSULE, HARD | ||||||||||
| 124183154 | 12418315 | 5 | SS | SUTENT | SUNITINIB MALATE | 1 | Oral | 50 MG, CYCLIC (2 WEEKS ON, 1 WEEK OFF) | 21938 | 50 | MG | CAPSULE, HARD | |||||||
| 124183154 | 12418315 | 6 | C | PAXIL | PAROXETINE HYDROCHLORIDE | 1 | 40 MG, 1X/DAY | 0 | 40 | MG | QD | ||||||||
| 124183154 | 12418315 | 7 | C | SPIRONOLACTONE. | SPIRONOLACTONE | 1 | 25 MG, UNK | 0 | 25 | MG | |||||||||
| 124183154 | 12418315 | 8 | C | LISINOPRIL. | LISINOPRIL | 1 | 40 MG, UNK | 0 | 40 | MG | |||||||||
| 124183154 | 12418315 | 9 | C | ZOCOR | SIMVASTATIN | 1 | 20 MG, UNK | 0 | 20 | MG | |||||||||
| 124183154 | 12418315 | 10 | C | TERAZOSIN | TERAZOSINTERAZOSIN HYDROCHLORIDE | 1 | 5 MG, UNK | 0 | 5 | MG | |||||||||
| 124183154 | 12418315 | 11 | C | VITAMIN C | ASCORBIC ACID | 1 | 1000 MG, UNK | 0 | 1000 | MG | |||||||||
| 124183154 | 12418315 | 12 | C | CALCIUM | CALCIUM | 1 | 1000 MG, UNK | 0 | 1000 | MG | |||||||||
| 124183154 | 12418315 | 13 | C | VITAMIN D | CHOLECALCIFEROL | 1 | 3000 MG, UNK | 0 | 3000 | MG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 124183154 | 12418315 | 1 | Renal cancer |
| 124183154 | 12418315 | 6 | Hypertension |
| 124183154 | 12418315 | 7 | Hypertension |
| 124183154 | 12418315 | 8 | Hypertension |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 124183154 | 12418315 | Ageusia | |
| 124183154 | 12418315 | Dizziness | |
| 124183154 | 12418315 | Dry skin | |
| 124183154 | 12418315 | Dysgeusia | |
| 124183154 | 12418315 | Dyspepsia | |
| 124183154 | 12418315 | Eating disorder | |
| 124183154 | 12418315 | Fatigue | |
| 124183154 | 12418315 | Pain | |
| 124183154 | 12418315 | Skin fragility | |
| 124183154 | 12418315 | Skin haemorrhage | |
| 124183154 | 12418315 | Tongue discomfort | |
| 124183154 | 12418315 | Weight decreased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 124183154 | 12418315 | 1 | 20160223 | 0 | ||
| 124183154 | 12418315 | 3 | 201602 | 0 | ||
| 124183154 | 12418315 | 5 | 201601 | 0 |